News Search Results
Jul 20, 2026, 07:00 ET BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx; Hemispherian AS
Jul 20, 2026, 03:00 ET Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Jul 13, 2026, 04:56 ET Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
covering multiple tumor types such as extrapulmonary neuroendocrine carcinoma (EP‑NEC), biliary tract cancer (BTC), and relapsed/refractory multiple myeloma (RRMM). In addition, the Company has been granted a Late‑Breaking Abstract (LBA) status and plans to submit the full LBA abstract in September.
More news about: Leads Biolabs
Jul 13, 2026, 00:00 ET Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Jul 10, 2026, 16:33 ET HealthTree Foundation Announces the Appointment of Lisa Gray to Its Board of Directors
revenue growth and deepen philanthropic support.Diagnosed with multiple myeloma in 2023, Lisa has since dedicated time to supporting fellow patients and advancing research that improves outcomes across the myeloma community. Her dual perspective—as both a seasoned philanthropic leader and a patient—will
More news about: HealthTree Foundation
Jul 08, 2026, 07:00 ET BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.; Hemispherian AS
Jul 01, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is
More news about: Karyopharm Therapeutics Inc.
Jun 23, 2026, 20:00 ET Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
6MW5311), for the treatment of hematologic malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). 6MW5311 is the first LILRB4/CD3 targeting TCE drug candidate globally to receive clinical trial approval. Previously, it received FDA
More news about: Mabwell
Jun 23, 2026, 10:00 ET HealthWell Foundation Achieves Milestone of Assisting Over Half a Million People Living with Cancer
Multiple Myeloma."As we continue to observe National Cancer Survivor's Month, HealthWell reaffirms our long-held commitment to serving the oncology community,"
More news about: HealthWell Foundation
Jun 22, 2026, 10:31 ET Hematopoietic Stem Cell Transplantation Market Landscape to Evolve at a CAGR of 12.4% During the Forecast Period (2026-2036) as Novel Therapies and Expanding Patient Eligibility Drive Growth | DelveInsight
Transplantation Market Increasing Prevalence of Hematologic Disorders: The rising incidence of leukemia, lymphoma, multiple myeloma, aplastic anemia, and inherited blood disorders is driving demand for HSCT as a potentially curative treatment option.Expansion of HSCT
More news about: DelveInsight Business Research, LLP
Jun 21, 2026, 20:30 ET Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Jun 21, 2026, 20:00 ET Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
immunotherapy option for patients with multiple myeloma. Looking ahead, Innovent will deepen its dual innovation in ADC and immunotherapy, and is committed to delivering cutting-edge therapies to patients worldwide."About Multiple MyelomaMultiple Myeloma is a malignant hematological malignancy
More news about: Innovent Biologics
Jun 19, 2026, 09:00 ET Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026
circRNA delivery to previously inaccessible cell types, unlocking treatments for intractable diseases such as systemic lupus erythematosus, multiple myeloma, plasma cell leukemia, hematopoietic stem cell disorders and neurodegenerative diseases. Founded by Fapon Group and circular RNA pioneer Dr. Alex Wesselhoeft,
More news about: Fapon Biopharma
Jun 18, 2026, 17:08 ET Johnson & Johnson recebe aprovação da Anvisa para TECVAYLI® (teclistamabe) em combinação com DALINVI® (daratumumabe) subcutâneo (SC) para mieloma múltiplo recidivado ou refratário, ampliando as opções de tratamento disponíveis para pacientes a partir da primeira recaída.
relapse after initial therapy in multiple myeloma. Blood, 138(Supplement 1), 3761. https://doi.org/10.1182/blood-2021-1512494 Rajkumar SV. Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification
More news about: Johnson & Johnson Innovative Medicine Brazil
Jun 18, 2026, 06:55 ET IASO Bio Announces NDA Approval of Equecabtagene Autoleucel by the Singapore Health Sciences Authority (HSA) for the Treatment of Relapsed or Refractory Multiple Myeloma, Marking a Key Milestone in International Commercialization
families."About Multiple Myeloma (MM)The global annual incidence of MM increased from 164,300 cases in 2019 to 197,200 cases in 2024, and is projected to reach 273,600 cases by 2040. Despite significant progress in modern anti-myeloma treatments, MM remains largely incurable
More news about: IASO Bio
Jun 17, 2026, 08:01 ET Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026
innovative therapies. Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, the Myeloma Investment Fund (MIF), GIBF and the Cancer Focus Fund. This study is supported by the European Innovation Council (EIC)KEYTRUDA®
More news about: Nectin Therapeutics, LTD.
Jun 16, 2026, 08:00 ET 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
system into a powerful anti-cancer medicine, creating breakthrough treatments for malignant blood diseases such as leukemia, lymphoma, and multiple myeloma.The pioneering work in this field was fundamentally established by Dr. Steven A. Rosenberg, widely known as the "Father of Cancer Immunotherapy."
More news about: The Tang Prize Foundation
Jun 14, 2026, 20:15 ET CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
Data for CT0596 in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell LeukemiaEight patients, including 6 relapsed/refractory multiple myeloma (R/RMM) and 2 relapsed/refractory primary plasma cell leukemia (R/R pPCL), received CT0596 at
More news about: CARsgen Therapeutics
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications,
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
combination regimen.3About Multiple MyelomaMultiple myeloma is a complex blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.4 In multiple myeloma, these plasma cells proliferate and spread rapidly and
More news about: Johnson & Johnson
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis
More news about: AbbVie
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Jun 04, 2026, 16:05 ET Bio Ascend™, a Vaniam Group™ Company, Assumes Stewardship of iwNHL™ and iwMyeloma™ Workshops, Building on the Longstanding Leadership of World Health Communications
today a strategic transition to advance the internationally recognized International Workshop on NHL (iwNHL) and International Workshop on Multiple Myeloma (iwMyeloma). Bio Ascend, Vaniam Group's medical education company, assumes leadership of the organization and delivery of both workshops, building
More news about: Vaniam Group LLC